P. Sagaster et al., TREATMENT OF ADVANCED COLORECTAL-CANCER WITH FOLINIC ACID AND 5-FLUOROURACIL IN COMBINATION WITH CISPLATINUM, European journal of cancer, 30A(9), 1994, pp. 1250-1254
51 patients with metastatic colorectal cancer (stage Dukes D) were tre
ated with intravenous (i.v.) infusion on days 1, 3, 5, 8 and 16 with f
olinic acid (200 mg/m(2)) and 5-fluorouracil (600 mg/m(2)), and on day
s 1, 8 and 16 with cisplatinum (25 mg/m(2) i.v.); cycles were repeated
every 4 weeks. All 51 patients were evaluable for toxicity and respon
se criteria. 26 patients had objective responses (3 complete responses
, 5.9%; 23 partial responses, 45.1%), relative risk 51% (95% confidenc
e intervals 36.7-65.0%). Response duration ranged from 4 to 28.0 month
s (median 16.8). Overall median survival of all patients included was
14.7 months (range 3.0-33.0). Toxicity of WHO grade III, requiring dos
e reduction, occurred in 9 (18%) patients. The regimen described here
appears to be active, safe and well tolerated for treatment of patient
s with advanced colorectal cancer.